Admission of Further Securities to Trading

AstraZeneca

Today 15:05

		
		
		
		
		
	
	
RNS Number : 2822B
  
AstraZeneca PLC
  
02 November 2026
  
 

		

			

				2 November 2026
			
			

				Notification of Admission of Further Securities to Trading (PRM 1.6.4R)
			
			

				The following notification is made in accordance with The Public Offers and Admissions to Trading Regulations 2024 (POATRs) PRM 1.6.4R.
			
			

				

					

						

							1
						
					
					

						

							Details of the issuer
						
					
				
				

					

						

							a)
						
					
					

						

							Name
						
					
					

						

							AstraZeneca PLC
						
					
				
				

					

						

							b)
						
					
					

						

							LEI
						
					
					

						

							PY6ZZQWO2IZFZC3IOL08
						
					
				
				

					

						

							2
						
					
					

						

							Details of the transferable securities admitted to trading
						
					
				
				

					

						

							a)
						
					
					

						

							Name, type and identification code
						
					
					

						

							Ordinary Shares of $0.25 each
						
						

							ISIN: GB0009895292
						
					
				
				

					

						

							b)
						
					
					

						

							Regulated market
						
					
					

						

							London Stock Exchange - Main Market
						
					
				
				

					

						

							c)
						
					
					

						

							Number of further securities issued and admitted
						
					
					

						

							11,948
						
					
				
				

					

						

							d)
						
					
					

						

							Total number of securities in issue following admission
						
					
					

						

							1,551,065,237
						
					
				
				

					

						

							e)
						
					
					

						

							Fungibility
						
					
					

						

							Fully fungible with existing Ordinary Shares
						
					
				
				

					

						

							3
						
					
					

						

							Admission details
						
					
				
				

					

						

							a)
						
					
					

						

							Date of admission
						
					
					

						

							Issued between 1 October 2026 to 31 October 2026 (admitted under a block admission dated 29 January 2021) 
						
					
				
				

					

						

							b)
						
					
					

						

							Prospectus information
						
					
					

						

							Prospectus: N/A
						
						

							Supplementary: N/A
						
						

							Company's webpage: https://www.astrazeneca.com
						
						

							 
						
					
				
				

					

						

							c)
						
					
					

						

							Coverage of notification
						
					
					

						

							Admission of shares under the Company’s employee share schemes from 1 October 2026 up to 31 October 2026, admitted to trading on the Main Market of the London Stock Exchange under the Company’s existing block admission of shares dated 29 January 2021.  
 
						
					
				
			
			

				 
			
			

				AstraZeneca
			
			

				AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Disease, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.
			
			

				 
			
			

				 
			
			

				Contacts
			
			

				For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
			
			

				 
			
			

				 
			
			

				Matthew Bowden
Company Secretary
			
			

				AstraZeneca PLC
			
			

				 
			
		
	
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
ADMGZMFGGGLGVZZ